<DOC>
	<DOCNO>NCT00908024</DOCNO>
	<brief_summary>The study expect identify safe dose BMS-754807 give combination standard dose cetuximab recommend dose dose range Phase II study . The study also intend collect first data effect combination BMS-754807 cetuximab tumor patient colorectal cancer squamous cell cancer head neck cetuximab-containing therapy effective</brief_summary>
	<brief_title>Combination Study BMS-754807 ErbituxÂ® Subjects With Advanced Metastatic Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>For additional information , please contact BMS oncology clinical trial information service 8552160126 email MyCancerStudyConnect @ emergingmed.com . Please visit www.BMSStudyConnect.com information clinical trial participation . ECOG status 0 1 Dose escalation : Subjects locally advance metastatic solid tumor eligible receive cetuximab treatment archive tumor biopsy material available . Colorectal cancer subject must confirm KRAS wild type Dose expansion : CRC ( KRASWT ) head &amp; neck cancer subject 1. must able provide 2 fresh tumor biopsy sample 2. must fail one prior cetuximabcontaining treatment Symptomatic brain metastasis Prior treatment antiEGFR ( except cetuximab ) antiIGF1R agent , experimental license Any condition require chronic use steroid Any disorder dysregulation glucose homeostasis ( history Type 1 2 Diabetes Mellitus prediabetic symptom ) History glucose intolerance History cetuximab infusion reaction Women childbearing potential unwilling unable use acceptable contraception method</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>